Actionable news
All posts from Actionable news
Actionable news in LPCN: LIPOCINE INC,

Analysts Bullish on Biotech Giants: Keryx Biopharmaceuticals, Inc. (KERX) and Lipocine Inc. (NASDAQ:LPCN)


Analysts are eager to weigh in on biotech giant Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) after new earnings results and Lipocine Inc. (NASDAQ:LPCN) after the company’s pipeline drug got a leg up on a competitor.

Keryx Biopharmaceuticals, Inc.

Keryx posted its 3Q15 earnings report on October 29, prompting analyst Jonathan Aschoff of Brean Capital to maintain a Buy rating on the stock with a price target of $18.

The biopharmaceutical company reported 3Q15 total revenue of $4.2 million, well over the consensus of $3.8 million. Aschoff explained, “The beat (is) mostly due to the more than typical fraction of sales made through the DaVita Rx and Fresenius Rx pharmacies, which are not captured by IMS;” the service that provides information on prescriptions.

US net sales of Auryxia, Keryx’s lead product used in patients undergoing dialysis for kidney disease, were $3.2 million, based on approximately 5,350 prescriptions filled in 3Q15, marking a 45% sequential increase in unit volume compared to 2Q15. Keryx started a sample program in May to target physicians who have not yet written an Auryxia prescription. Aschoff estimated, “Keryx is on track with its sample program, and we expect a faster uptake in Auryxia sales as the starter kit pill count drops...